In various implementations, one or more compositions may be provided to improve or maintain oral and/or intestinal health. For example, a dental powder, toothpaste, mouthwash, and/or probiotic composition may be administered to improve or maintain oral and/or intestinal health. In some implementations, an intestinal health kit that includes cleanse compositions, renewal compositions, and/or digestion aids (e.g., enzymes) may be administered to improve or maintain intestinal health and/or fitness.

The inventions described herein relate generally to digestive healthcare, and more particularly, to the feeding of mammals, particularly human infants, who are making a transition from a microbiome with lower diversity to a microbiome with higher diversity. These inventions relate to certain foods comprising a fermentable nutritional component and a probiotic component, where the probiotic component is selected, based on genetic and/or metabolic criteria, to specifically metabolize any Free Sugar Monomers (FSMs) and Free Amino Acids (FAAs) or peptides that accumulate as a result of the fermentable nutritional component in the lower intestine, where they otherwise might be left in the environment to be fermented and metabolized by less adapted/opportunistic bacteria, creating blooms of deleterious intestinal bacteria and shifting the microbiome to a potentially dysbiotic state. The present inventions provide combinations of foods and probiotic bacteria that can protect the mammalian gut from blooms of pathogenic bacteria under the circumstances where the mammalian gut is starting out with a low microbial diversity, such as in weaning infants, or individuals who are post-antibiotic treatment and/or post-chemotherapeutic treatment and transitioning to a higher diversity adapted/stable microbiome.

A composition comprising combination of salt, sugar and lactic acid bacteria as an active ingredient to treat vaginosis. The composition showed potent antibacterial activity through various experiments, for example, (1) the indirect inhibitory activity test from the growth of vaginosis causing bacteria by determining the change of pH and lactic acid level; (2) the direct inhibitory activity test from the growth of vaginosis causing bacteria by determining the susceptibility of test sample; (3) brief clinical tests, and finally confirmed that the combination showed potent antibacterial activity in the test. Accordingly, the combination may be useful to alleviate and treat vaginosis in the form of a pharmaceutical composition, health functional food, food additive, topical composition, and detergent composition.

Processes for producing a nutritional supplement that contains sulforaphane, and supplements formed thereby. Such a process includes combining a cruciferous vegetable, for example, broccoli sprouts, with strains of Lactobacillus, Streptococcus and Bifidobacterium to form a mixture, causing the mixture to undergo lactic acid fermentation, transform a glucosinolate within the cruciferous vegetable to sulforaphane, and yield a fermented mixture that contains sulforaphane, and then producing from the fermented mixture a supplement that can be ingested by an individual.

The present disclosure relates to novel sialidase enzymes having a preference for cleaving N-glycolylneuraminic acid (Neu5Gc) from glycoconjugates over cleaving N-acetyineuraminic acid (Neu5Ac). The present disclosure further provides the polypeptide of such novel sialidase and its catalytic pockets; the recombinant host cells expressing the same, as well as the enzymatic, pharmaceutical, and consumable compositions comprising such novel sialidases. Probiotic compositions comprising a bacterium that expresses the sialidase having a preference for Neu5Gc over Neu5Ac, and methods for removing Neu5Gc from consumable products are also provided. Also disclosed are methods for treating or preventing various diseases, disorders, and inflammatory conditions in a subject using the novel sialidases.

Provided herein is an anti-allergic agent for ameliorating an allergic disease in infants, particularly newborns, without causing side effects. The anti-allergic agent for infants comprises a bifidobacterium.

An animal feed supplement that includes dry Enterococcus faecium Fermentation Product, dry Bacillus subtilis Fermentation Product, dry Bacillus licheniformis Fermentation Product, dry Lactobacillus casei Fermentation Product, dry Lactobacillus plantarum Fermentation Product, dry Lactobacillus acidophilus Fermentation Product, dry Bifidobacterium bifidum Fermentation Product, dry Pediococcus acidilactici Fermentation Product, dry Pediococcus pentosaceus Fermentation Product; and dry Lactobacillus lactis Fermentation Product.

The disclosure relates to the field of medicine and nutrition, more specifically, to the field of treatment and prevention of human disorders such as depression, rumination, aggression, migraine, autistic spectrum disorders (including autism and ADHD), schizophrenia, chronic fatigue, kidney disorders, metabolic syndrome or diabetes type II. The disclosure provides a pharmaceutical or food composition or a supplement comprising a multispecies probiotic composition at least comprising Bifidobacterium bifidum W23 for use in the treatment or prevention of disorders in humans and methods to use such a pharmaceutical or food composition or a supplement.

The disclosure relates to the field of medicine and nutrition, more specifically, to the field of treatment and prevention of human disorders such as depression, rumination, aggression, migraine, autistic spectrum disorders (including autism and ADHD), schizophrenia, chronic fatigue, kidney disorders, metabolic syndrome or diabetes type II. The disclosure provides a pharmaceutical or food composition or a supplement comprising a multispecies probiotic composition at least comprising Bifidobacterium bifidum W23 for use in the treatment or prevention of disorders in humans and methods to use such a pharmaceutical or food composition or a supplement.

Novel Bifidobacterium bacteria having an opioid peptide decomposition action and a noncollagenous glycoprotein decomposition action are provided. The present invention relates to one or more kinds of Bifidobacterium bacteria selected from the group consisting of Bifidobacterium bifidum MCC1092 (NITE BP-02429), Bifidobacterium bifidum MCC1319 (NITE BP-02431), Bifidobacterium bifidum MCC1868 (NITE BP-02432), Bifidobacterium bifidum MCC1870 (NITE BP-02433), and Bifidobacterium longum subsp. longum MCC1110 (NITE BP-02430), as well as a composition for decomposing an opioid peptide and composition for decomposing a noncollagenous glycoprotein containing the Bifidobacterium bacteria as an active ingredient.